Faculty Articles

Translating Mutagenesis into Carcinogenesis

Publication Title

Journal of Carcinogenesis and Mutagenesis

ISSN

2157-2518

Publication Date

6-1-2012

Abstract

Genotoxicity provided the rationale for systemic cancer therapy, which is only, now, after 70 years or so, giving way to new modalities. It is becoming standard practice to evaluate the genome and/or transcriptome of cancers in order to tailor targeted therapies using antibodies (and now, fusion antibodies), small molecule inhibitors, and, in the near future, microRNAs, both native and engineered. These methods usually target the altered or over expressed products of activated oncogenes; normal cellular genes activated by site-specific mutation. It is, however, at the level of prevention where the field of genotoxicity has made its greatest contributions to human health, and where it may play its most important roles in the future. It is impossible to estimate the number of cancer cases prevented by the governmental and industrial screening of chemicals and products for mutagenic activity, which have then not been introduced into wide human contact.

DOI

10.4172/2157-2518.1000e106

Volume

3

Issue

1

Disciplines

Medical Specialties | Medicine and Health Sciences | Osteopathic Medicine and Osteopathy

This document is currently not available here.

Peer Reviewed

Find in your library

Share

COinS